Predictors of Sustained Response and Effects of Anti-CGRP Antibodies Discontinuation and Reinitiation in Resistant Chronic Migraine.
Sign Up to like & getrecommendations! Published in 2022 at "European journal of neurology"
DOI: 10.1111/ene.15260
Abstract: BACKGROUND Guidelines for migraine prophylaxis suggest stopping medication after 6-12 months to reevaluate treatment appropriateness. The Italian Medicines Agency (AIFA) set a mandatory regulation to stop anti-CGRP (calcitonin gene related protein) pathway monoclonal antibody (anti-CGRP… read more here.
Keywords: chronic migraine; discontinuation; treatment; response ... See more keywords
Machine-learning based approach to predict CGRP response in patients with migraine: multicenter Spanish study.
Sign Up to like & getrecommendations! Published in 2022 at "European journal of neurology"
DOI: 10.1111/ene.15458
Abstract: BACKGROUND To date, several variables have been associated with anti-CGRP receptor or ligand-antibody response with disparate results. Our objective is to determine whether machine learning (ML)-based models can predict 6, 9 and 12 months response… read more here.
Keywords: patients migraine; cgrp; machine learning; learning based ... See more keywords
Detoxification vs non-detoxification before starting an anti-CGRP monoclonal antibody in medication overuse headache
Sign Up to like & getrecommendations! Published in 2022 at "Cephalalgia"
DOI: 10.1177/03331024211067791
Abstract: Abstract Background Medication overuse headache significantly contributes to the chronification process and treatment refractoriness of migraine. Currently, abrupt discontinuation of the overused medication still represents the best management strategy for these patients, challenging public health… read more here.
Keywords: medication; detoxification; overuse headache; headache ... See more keywords
Anti-Calcitonin Gene-Related Peptide Monoclonal Antibodies in the Treatment of Patients With Concussion
Sign Up to like & getrecommendations! Published in 2022 at "Neurology"
DOI: 10.1212/01.wnl.0000801812.93958.f8
Abstract: Objective Investigate the efficacy of 3 anti-Calcitonin Gene-Related Peptide monoclonal antibodies (anti-CGRP mAbs), fremanezumab, galcanezumab, and erenumab, in concussion patients with post-traumatic headache (PTH) with a migraine phenotype. Background A study using monoclonal antibodies in… read more here.
Keywords: headache; cgrp mabs; treatment; anti cgrp ... See more keywords
Blood Pressure in Migraine Patients Treated With Monoclonal Anti-CGRP (receptor) Antibodies: A Prospective Follow-up Study.
Sign Up to like & getrecommendations! Published in 2022 at "Neurology"
DOI: 10.1212/wnl.0000000000201008
Abstract: BACKGROUND AND OBJECTIVES Anti-CGRP (receptor) antibodies are approved as preventive treatment for migraine. Recent concerns have been raised after a retrospective analysis of post-marketing case reports of elevated BP associated with erenumab. In this prospective… read more here.
Keywords: receptor antibodies; cgrp receptor; blood pressure; anti cgrp ... See more keywords
Late Response to Anti-CGRP Monoclonal Antibodies in Migraine: A Multicenter, Prospective, Observational Study.
Sign Up to like & getrecommendations! Published in 2023 at "Neurology"
DOI: 10.1212/wnl.0000000000207292
Abstract: OBJECTIVES To assess frequency and characteristics of late responders (>12 weeks) to monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP). METHODS This is a multicenter (n=16), prospective, real-life study, considering all consecutive adults with… read more here.
Keywords: multicenter prospective; cgrp mabs; late responders; monoclonal antibodies ... See more keywords
Rodent behavior following a dural inflammation model with anti-CGRP migraine medication treatment
Sign Up to like & getrecommendations! Published in 2023 at "Frontiers in Neurology"
DOI: 10.3389/fneur.2023.1082176
Abstract: Background Migraine is a widespread and prevalent disease with a complex pathophysiology, of which neuroinflammation and increased pain sensitivity have been suggested to be involved. Various studies have investigated the presence of different inflammatory markers… read more here.
Keywords: inflammation; test; cfa; model ... See more keywords
Semi-Automated Recording of Facial Sensitivity in Rat Demonstrates Antinociceptive Effects of the Anti-CGRP Antibody Fremanezumab
Sign Up to like & getrecommendations! Published in 2023 at "Neurology International"
DOI: 10.3390/neurolint15020039
Abstract: Migraine pain is frequently accompanied by cranial hyperalgesia and allodynia. Calcitonin gene-related peptide (CGRP) is implicated in migraine pathophysiology but its role in facial hypersensitivity is not entirely clear. In this study, we investigated if… read more here.
Keywords: antibody; facial sensitivity; antibody fremanezumab; anti cgrp ... See more keywords
Pooled Analysis of Real-World Evidence Supports Anti-CGRP mAbs and OnabotulinumtoxinA Combined Trial in Chronic Migraine
Sign Up to like & getrecommendations! Published in 2022 at "Toxins"
DOI: 10.3390/toxins14080529
Abstract: OnabotulinumtoxinA, targeting the CGRP machinery, has been approved for the last two decades for chronic migraine prevention. The recently approved monoclonal antibodies (mAbs) directed towards the calcitonin gene-related peptide (CGRP) pathway open a new age… read more here.
Keywords: mabs onabotulinumtoxina; cgrp mabs; chronic migraine; evidence ... See more keywords